{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-003779","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2024-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.881376+00:00","generated_at":"2026-06-01T09:43:53.919110+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Xenetic Biosciences CEO Eisenberg and CSO Lockshin depart; CFO Parslow named interim CEO","bullets":["Jeffrey F. Eisenberg stepped down as CEO and resigned as director effective May 16, 2024.","Dr. Curtis Lockshin stepped down as Chief Scientific Officer, effective May 16, 2024.","James F. Parslow, CFO since April 2017, appointed interim CEO; continues as principal financial officer.","Parslow is a CPA with over 35 years experience; no related-party transactions or family relationships noted.","Company advancing DNase oncology program toward Phase 1; preclinical data expected before year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-003779","json":"https://secwatch.observer/filing/0001683168-24-003779.json","markdown":"https://secwatch.observer/filing/0001683168-24-003779.md","text":"https://secwatch.observer/filing/0001683168-24-003779.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316824003779/0001683168-24-003779-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316824003779/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:43:53.919110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"24f83cbf9c","claim":"Jeffrey F. Eisenberg resigned as Director at Xenetic Biosciences, Inc..","evidence_excerpt":"and in connection therewith, Mr. Eisenberg resigned as a director of the Company and all of its subsidiaries, as applicable.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534525/000168316824003779/0001683168-24-003779-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"29e4f710a5","claim":"Dr. Curtis Lockshin departed as Chief Scientific Officer at Xenetic Biosciences, Inc..","evidence_excerpt":"In addition on May 16, 2024, the Company and Dr. Curtis Lockshin mutually agreed that Dr. Lockshin would step down as the Chief Scientific Officer of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534525/000168316824003779/0001683168-24-003779-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"698040fd8d","claim":"Jeffrey F. Eisenberg departed as Chief Executive Officer at Xenetic Biosciences, Inc..","evidence_excerpt":"On May 16, 2024, the Company and Jeffrey F. Eisenberg mutually agreed that Mr. Eisenberg would step down as the Chief Executive Officer of the Company, effective immediately","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534525/000168316824003779/0001683168-24-003779-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"7eadf65f89","claim":"James F. Parslow was appointed as Interim Chief Executive Officer at Xenetic Biosciences, Inc..","evidence_excerpt":"On May 16, 2024, the Board of Directors (the “Board”) of Xenetic Biosciences, Inc. (the “Company”) appointed James F. Parslow, the Company’s Chief Financial Officer, to the position of Interim Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534525/000168316824003779/0001683168-24-003779-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}